NephCure Unveils New Mission Focusing on New Era of Access
For more than a quarter century, NephCure has worked alongside patients, caregivers, researchers, industry, and physicians to transform the rare kidney disease (RKD) landscape. When NephCure was first founded, there was little scientific understanding of RKD, no FDA-approved treatments, and virtually no drugs in development.
As scientific breakthroughs accelerate, NephCure recognizes FDA-approved treatments are not the finish line, but rather the starting line. Too many families still face barriers, and to meet this moment, NephCure introduces its new mission statement. Click the button below to learn more about our new mission.
Help Shape The Future of NephCure: Community Feedback Survey
Our community is strongest when your voice is part of the conversation. Whether you’re a patient, caregiver, or loved one, your experiences matter, and they shape the work we do every day. By taking this brief survey below, you’re helping guide the future of NephCure’s programs, resources, and advocacy efforts.
Together, your input helps us build a stronger, more supportive community for everyone affected by rare kidney disease.
Letter to the NephCure Community: Update on FDA Decision About Sparsentan for FSGS
The U.S. Food and Drug Administration (FDA) has been reviewing an application for FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The initial date for the FDA to make a decision on this drug was January 13, 2026. On that date, the FDA issued what is called a major amendment, which means the review process will take more time.
To help provide more clarityon what this update means and answer any questions you may have related to this important update, NephCure is hosting a virtualFSGS Community Town Hall on Wednesday, January 21st at 7pm ET. Anyone impacted by FSGS should join this important conversation. Click below to register and submit your questions to have them answered.
2026 Patient & Youth Summit Registration is Now Open!
The moment we’ve all been waiting for is finally here — registration is now open for the 2026 NephCure Patient Summit and Youth Summit!
We are thrilled to welcome our community to New Orleans, Louisiana, for an unforgettable weekend at the Hyatt Regency New Orleans, taking place June 25–27, 2026. This annual gathering brings together patients, caregivers, families, advocates, and healthcare partners from across the country who share a connection to rare, protein-spilling kidney diseases. Don't miss out and register now!
Harper is a 7-year-old girl living with focal segmental glomerulosclerosis (FSGS), a rare kidney disease that affects her daily life in ways most kids her age never have to think about.
Despite facing constant challenges with rare kidney disease, Harper is still incredibly brave, courageous, and kind. Click below to learn more about Harper!
Dealing with Insurance Headaches for Your Diagnosis?
Rare kidney disease patients have some unique challenges when dealing with insurance coverage for their treatments. Click the button below for some tips to help you be your own best advocate when it comes to insurance headaches.
Jennifer Moore, a Masters Level Registered Dietitian, presented a session for patients and caregivers surrounding treating inflammation through diet for kidney disease and how to treat it. Watch the full video below for more information!
NephCure's mission is to empower people with rare, protein-spilling kidney disease to take charge of their health, while leading the revolution in research, new treatments, and care.